CirCode is an innovative biotechnology company based in China, founded in 2021. The company focuses on the development of Circular RNA therapeutics, with a commitment to realizing the full potential of mRNA science for patients. Compared to linear RNA, circular RNA is more stable and less immunogenic, providing superiority in a broader therapeutic area. CirCode has developed proprietary platform technologies and holds multiple patent families covering this new technology with pending applications worldwide. The company's last investment was a Series A investment on 15 August 2023. The investors in this round included Johnson & Johnson Innovation – JJDC and Chaoxian Fund. CirCode aims to promote the transformation of scientific and technological achievements for the benefit of mankind. For more information, please visit www.circodebio.com.
General Information
BounceWatch is an independent company data service, not affiliated with 环码. To contact 环码, visit circodebio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
China Market
Biotechnology
About 环码
Taxonomy: Innovative, Circular RNA, Therapeutics, Drug Development, Platform Technologies, Patent, Scientific Advancement, Technological Achievements, Nucleic Acid Drugs, Pharmaceutical, Medical Research, RNA, Biomedical
Funding Rounds & Investors (2)
View All环码 Alternatives & Competitors
View All AlternativesA messenger RNA medicines company focused on the development of liver and respiratory rare disease t...
Enabling Nucleic Acid Medicines for Next‑Generation Therapies | www.etherna.be
FAQ About 环码
Source: BounceWatch company record for 环码, https://bouncewatch.com/company/circode, updated 21 October 2024. When citing, please name BounceWatch and link this page.